• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells

6 de July de 2023
Lancet Oncol. 2023 Jul;24(7):715-717. doi: 10.1016/S1470-2045(23)00283-8.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-07-06 10:00:002023-07-06 10:00:00γ-Secretase inhibitors plus anti-BCMA chimeric antigen receptor T cells

MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes

4 de July de 2023
Eur J Hum Genet. 2023 Oct;31(10):1185-1189. doi: 10.1038/s41431-023-01418-5.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-07-04 10:00:002023-07-04 10:00:00MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

3 de July de 2023
Oncotarget. 2023 Jul 1;14:668. doi: 10.18632/oncotarget.28471.NO…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-07-03 10:00:002023-07-03 10:00:00Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma

Cellular therapy in lymphoma

29 de June de 2023
Hematol Oncol. 2023 Jun 29. doi: 10.1002/hon.3200. Online ahead…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-06-29 10:00:002023-06-29 10:00:00Cellular therapy in lymphoma

Target 2035 – an update on private sector contributions

26 de June de 2023
RSC Med Chem. 2023 Mar 16;14(6):1002-1011. doi: 10.1039/d2md00441k.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-06-26 10:00:002023-06-26 10:00:00Target 2035 – an update on private sector contributions

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

10 de June de 2023
Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.ABSTRACTHematological…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-06-10 10:00:002023-06-10 10:00:00Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

5 de June de 2023
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-06-05 10:00:002023-06-05 10:00:00Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

5 de June de 2023
Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-06-05 10:00:002023-06-05 10:00:00Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases

24 de May de 2023
Eur J Intern Med. 2023 Sep;115:10-17. doi: 10.1016/j.ejim.2023.05.020.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-24 10:00:002023-05-24 10:00:00Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases

The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world

23 de May de 2023
Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S15-S24. doi: 10.31547/bct-2022-013.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-23 10:00:002023-05-23 10:00:00The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world

Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis

22 de May de 2023
Cancer Med. 2023 Jul;12(13):14062-14071. doi: 10.1002/cam4.6058.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-22 10:00:002023-05-22 10:00:00Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis

PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

12 de May de 2023
NPJ Breast Cancer. 2023 May 12;9(1):37. doi: 10.1038/s41523-023-00546-x.ABSTRACTWe…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-05-12 10:00:002023-05-12 10:00:00PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants
Page 24 of 87«‹2223242526›»

Filter by categories

  • Alemany’s & Piulats’s lab (133)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sin categoría (5)
  • Sureda's & Farre's Lab (312)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}